Blueprint Medicines Corporation
LSE:0HOJ Stok Raporu
Blueprint Medicines Gelecekteki Büyüme
Future kriter kontrolleri 6/6 Blueprint Medicines kazanç ve gelirin sırasıyla yıllık 68.9% ve 25.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 68.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 47% olacağı tahmin edilmektedir.
Anahtar bilgiler Biotechs kazanç büyümesi 37.3% Gelir büyüme oranı 25.3% Gelecekteki özkaynak getirisi 47.0% Analist kapsamı Good
Son güncelleme 31 Oct 2024
Gelecekteki son büyüme güncellemeleri
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 Nov 02
No longer forecast to breakeven Aug 02
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024 Aug 01
Forecast to breakeven in 2026 Jul 24
No longer forecast to breakeven May 04 Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 May 03
Tüm güncellemeleri göster
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 Nov 02
Third quarter 2024 earnings released: US$0.89 loss per share (vs US$2.20 loss in 3Q 2023) Oct 31
Blueprint Medicines Corporation to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
No longer forecast to breakeven Aug 02
Second quarter 2024 earnings released: US$0.80 loss per share (vs US$2.19 loss in 2Q 2023) Aug 02
Blueprint Medicines Corporation Raises Revenue Guidance for the Full Year 2024 Aug 01
Forecast to breakeven in 2026 Jul 24
Blueprint Medicines Corporation to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Chief Scientific Officer recently sold US$421k worth of stock Jun 10
Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting May 24
No longer forecast to breakeven May 04 Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024 May 03
First quarter 2024 earnings released: EPS: US$1.45 (vs US$2.16 loss in 1Q 2023) May 03
Blueprint Medicines Corporation, Annual General Meeting, Jun 12, 2024 Apr 28
New minor risk - Share price stability Apr 24
Blueprint Medicines Corporation to Report Q1, 2024 Results on May 02, 2024 Apr 20
President recently sold US$1.1m worth of stock Mar 13
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting Feb 24
New minor risk - Shareholder dilution Feb 17
Forecast to breakeven in 2026 Feb 16
Full year 2023 earnings released: US$8.37 loss per share (vs US$9.35 loss in FY 2022) Feb 16
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024 Feb 15
Blueprint Medicines Corporation to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis Dec 13
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting Dec 11
Blueprint Medicines' Ayvakyt (Avapritinib) Receives Positive Chmp Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis Nov 12
Third quarter 2023 earnings released: US$2.20 loss per share (vs US$2.23 loss in 3Q 2022) Oct 27
New major risk - Share price stability Oct 27
Blueprint Medicines Corporation to Report Q3, 2023 Results on Oct 26, 2023 Oct 13
Second quarter 2023 earnings released: US$2.19 loss per share (vs US$2.68 loss in 2Q 2022) Aug 04
Chief Scientific Officer recently sold US$120k worth of stock Jun 08
Blueprint Medicines Announces Clinical Data for Multiple Programs Across its Precision Therapy Portfolio at the 2023 American Society of Clinical Oncology Jun 04
Blueprint Medicines Corporation Announces NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT (avapritinib) in Patients with Indolent Systemic Mastocytosis May 24
Blueprint Medicines Corporation Announces U.S. Food and Drug Administration Approves AYVAKIT(R) (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis May 23
Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2023 May 05
First quarter 2023 earnings released: US$2.16 loss per share (vs US$1.79 loss in 1Q 2022) May 05
Insider recently sold US$77k worth of stock Mar 10
Full year 2022 earnings released: US$9.35 loss per share (vs US$11.01 loss in FY 2021) Feb 18
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year of 2023 Feb 17
Blueprint Medicines Corporation Announces Partial Clinical Hold for Phase 1/2 Vela Trial of Blu-222 Feb 11
Blueprint Medicines Corporation to Report Q4, 2022 Results on Feb 16, 2023 Feb 10
Blueprint Medicines Corporation Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT(R) Jan 24
Blueprint Medicines Corporation Announces Board Changes Jan 07
Blueprint Medicines Corporation Reports Clinical Data Highlighting Leadership in Developing Targeted Treatment Options for Patients with Systemic Mastocytosis Dec 12
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT® (Avapritinib) for the Treatment of Indolent Systemic Mastocytosis Nov 23
Third quarter 2022 earnings released: US$2.23 loss per share (vs US$2.00 loss in 3Q 2021) Nov 02
Blueprint Medicines Corporation Provides Revenue Guidance for 2022 Nov 02
President of Research & Development recently sold US$234k worth of stock Oct 13
Blueprint Medicines Corporation Announces CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis Aug 25
Blueprint Medicines Announces Positive Top-Line Results from Pioneer Trial of AYVAKIT® (Avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints Aug 18
Insider recently sold US$314k worth of stock Aug 10
Second quarter 2022 earnings released: US$2.68 loss per share (vs US$1.86 loss in 2Q 2021) Aug 04
Blueprint Medicines Corporation Provides Revenue Guidance for 2022 Aug 03 Blueprint Medicines Corporation announced that it expects to receive $400 million in funding from Sixth Street Partners Jul 02
Blueprint Medicines Appoints Habib Dable to its Board of Directors Jun 24
Chief Scientific Officer recently sold US$114k worth of stock Jun 09
Insufficient new directors May 31
Blueprint Medicines Corporation Provides Revenue Guidance for the Year 2022 May 05
Blueprint Medicines Corporation, Annual General Meeting, Jun 21, 2022 May 02
Blueprint Medicines Corporation Announces Blu-945 Proof-Of-Concept Data Supporting Initiation of Comprehensive Combination Development Strategy in Egfr-Mutant Non-Small Cell Lung Cancer Apr 09
Blueprint Medicines Corporation and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader Therapies Mar 01
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 17
Blueprint Medicines Corporation Provides Earnings Guidance for 2022 Feb 17
Blueprint Medicines Corporation to Report Q4, 2021 Results on Feb 16, 2022 Feb 10
Blueprint Medicines Corporation's AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis Jan 30
Insufficient new directors Jan 04
Blueprint Medicines Corporation (NasdaqGS:BPMC) completed the acquisition of Lengo Therapeutics, Inc. Dec 31
Blueprint Medicines Corporation Publishes Results from Two Registration Studies of Ayvakit® (Avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis Dec 09
Insufficient new directors Dec 06
Blueprint Medicines Corporation (NasdaqGS : BPMC) agreed to acquire Lengo Therapeutics, Inc. for $470 million. Nov 30
Third quarter 2021 earnings released: US$2.00 loss per share (vs US$11.49 profit in 3Q 2020) Oct 31
President of Research & Development recently sold US$318k worth of stock Oct 08
Second quarter 2021 earnings released: US$1.86 loss per share (vs US$2.28 loss in 2Q 2020) Aug 02
High number of new directors Jul 31
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis Jun 17
Independent Chairman of the Board Daniel Lynch has left the company Jun 09
Blueprint Medicines Corporation Presents ARROW Trial Data for GAVRETO® May 21
First quarter 2021 earnings released: US$1.72 loss per share (vs US$2.11 loss in 1Q 2020) May 01
Investor sentiment improved over the past week Mar 12
CEO, President & Director recently sold US$779k worth of stock Mar 06
Revenue beats expectations Feb 18
Full year 2020 earnings released: EPS US$5.76 (vs US$7.27 loss in FY 2019) Feb 18
Blueprint Medicines Corporation to Report Q4, 2020 Results on Feb 17, 2021 Feb 11
Kazanç ve Gelir Büyüme Tahminleri LSE:0HOJ - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions ) Tarih Gelir Kazançlar Serbest Nakit Akışı Faaliyetlerden Nakit Avg. Analist Sayısı 12/31/2026 949 86 98 228 17 12/31/2025 712 -84 -30 43 17 12/31/2024 508 -74 -205 58 17 9/30/2024 434 -128 -251 -242 N/A 6/30/2024 363 -205 -348 -333 N/A 3/31/2024 282 -288 -430 -415 N/A 12/31/2023 249 -507 -453 -437 N/A 9/30/2023 216 -555 -492 -479 N/A 6/30/2023 226 -554 -515 -505 N/A 3/31/2023 205 -581 -503 -493 N/A 12/31/2022 204 -558 -511 -502 N/A 9/30/2022 272 -718 -404 -395 N/A 6/30/2022 230 -702 -367 -361 N/A 3/31/2022 221 -650 -310 -306 N/A 12/31/2021 180 -644 -302 -299 N/A 9/30/2021 107 -411 -312 -309 N/A 6/30/2021 828 340 407 409 N/A 3/31/2021 809 325 369 371 N/A 12/31/2020 794 314 384 387 N/A 9/30/2020 811 333 361 367 N/A 6/30/2020 75 -395 -340 -327 N/A 3/31/2020 72 -371 -321 -307 N/A 12/31/2019 67 -348 -292 -278 N/A 9/30/2019 16 -362 -311 -301 N/A 6/30/2019 8 -340 -291 -284 N/A 3/31/2019 44 -267 -214 -206 N/A 12/31/2018 45 -237 -188 -175 N/A 9/30/2018 45 -205 -165 -142 N/A 6/30/2018 52 -170 N/A -114 N/A 3/31/2018 17 -177 N/A -138 N/A 12/31/2017 21 -148 N/A -120 N/A 9/30/2017 27 -120 N/A -104 N/A 6/30/2017 26 -99 N/A -96 N/A 3/31/2017 27 -85 N/A -86 N/A 12/31/2016 28 -72 N/A -25 N/A 9/30/2016 25 -67 N/A -19 N/A 6/30/2016 22 -63 N/A -13 N/A 3/31/2016 18 -58 N/A -6 N/A 12/31/2015 11 -56 N/A -32 N/A 9/30/2015 7 -57 N/A -30 N/A 6/30/2015 3 -56 N/A -26 N/A 3/31/2015 1 -52 N/A -24 N/A 12/31/2014 N/A -46 N/A -35 N/A
Daha fazla göster
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 0HOJ önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.1% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: 0HOJ önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: 0HOJ önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: 0HOJ şirketinin gelirinin (yıllık 25.3% ) UK pazarından (yıllık 3.6% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 0HOJ şirketinin gelirinin (yıllık 25.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 0HOJ 'nin Özsermaye Getirisi 'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 47 %).
Büyüyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}